CRIS Current Research Information System

MARINELLI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.360
AS - Asia 1.986
EU - Europa 1.419
AF - Africa 147
Continente sconosciuto - Info sul continente non disponibili 137
SA - Sud America 98
OC - Oceania 1
Totale 6.148
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.314
VN - Vietnam 739
SG - Singapore 474
CN - Cina 393
IT - Italia 361
GB - Regno Unito 242
SE - Svezia 195
DE - Germania 174
HK - Hong Kong 117
FR - Francia 85
IN - India 77
NL - Olanda 69
BR - Brasile 68
RU - Federazione Russa 56
IE - Irlanda 51
BD - Bangladesh 40
FI - Finlandia 40
ZA - Sudafrica 40
CA - Canada 36
JP - Giappone 35
TG - Togo 35
UA - Ucraina 34
SC - Seychelles 33
CH - Svizzera 24
PH - Filippine 18
EE - Estonia 17
BG - Bulgaria 16
CI - Costa d'Avorio 15
EU - Europa 15
JO - Giordania 14
KR - Corea 14
TH - Thailandia 14
AR - Argentina 10
AT - Austria 10
BE - Belgio 10
ID - Indonesia 9
NG - Nigeria 9
PL - Polonia 9
ES - Italia 8
IQ - Iraq 8
TW - Taiwan 7
CL - Cile 6
LT - Lituania 6
TR - Turchia 6
CO - Colombia 5
MX - Messico 5
PY - Paraguay 5
MA - Marocco 4
MY - Malesia 4
UZ - Uzbekistan 4
HR - Croazia 3
PE - Perù 3
PK - Pakistan 3
SN - Senegal 3
DZ - Algeria 2
GH - Ghana 2
GR - Grecia 2
JM - Giamaica 2
KE - Kenya 2
LV - Lettonia 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LC - Santa Lucia 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.027
Salva come PNG Salva come JPEG
Città #
Singapore 339
Ashburn 266
Dong Ket 217
Southend 214
Fairfield 209
Chandler 185
Ho Chi Minh City 151
San Jose 151
Hanoi 120
Hong Kong 105
Seattle 99
Wilmington 91
Woodbridge 87
Houston 80
Bologna 78
Santa Clara 72
Princeton 56
Boardman 54
Cambridge 54
Dublin 51
Ann Arbor 50
Los Angeles 46
Council Bluffs 40
Beijing 37
Lauterbourg 35
Lomé 35
Helsinki 32
New York 32
Dallas 30
Da Nang 29
Tokyo 28
Padova 24
Westminster 22
Chicago 21
Dearborn 21
Frankfurt am Main 21
Berlin 20
Bern 20
Nanjing 20
Haiphong 18
Hefei 18
Jinan 18
Milan 16
Sofia 16
Abidjan 15
Munich 15
Amman 13
Buffalo 13
Guangzhou 13
Johannesburg 13
Phoenix 13
Saint Petersburg 13
Turin 13
Jacksonville 12
Nanchang 12
San Diego 12
Shanghai 12
São Paulo 12
Toronto 12
Florence 11
Redondo Beach 11
Amsterdam 10
Brussels 10
Düsseldorf 10
Montreal 10
Abeokuta 9
Changsha 9
Seoul 9
Shenzhen 8
Tianjin 8
Bangkok 7
Des Moines 7
Hangzhou 7
Naples 7
Palermo 7
Bühl 6
Bến Tre 6
Catanzaro 6
Hebei 6
Medford 6
Nuremberg 6
Rome 6
Shenyang 6
Thái Bình 6
Warsaw 6
Atlanta 5
Bremen 5
Brooklyn 5
Falkenstein 5
Imola 5
Jakarta 5
Kunming 5
Olalla 5
Orem 5
Paris 5
Redwood City 5
Sassari 5
Turku 5
Vienna 5
Xi'an 5
Totale 3.796
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 289
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 273
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 255
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 243
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 242
Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study 242
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 239
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 237
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 232
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 215
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 215
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 205
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 201
Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients 181
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 179
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. 176
Early Prediction of Treatment Response to Sorafenib with Elastosonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. 171
The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives 165
null 164
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study 163
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 156
Experience with regorafenib in the treatment of hepatocellular carcinoma 153
Erratum to: Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry (Intern Emerg Med, 10.1007/s11739-016-1416-8) 140
Letter to the editor. 135
Ipertensione portale. 135
Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. 132
The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. 118
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 109
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 94
Sorafenib versus Y90 radioembolization in cirrhotic patients with hepatocellular carcinoma (HCC): cohort and nested control-case study with propensity analysis 89
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib 86
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC 84
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 82
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 78
null 77
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 74
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 61
Neutrophil–lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry 58
Totale 6.148
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.326
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.326
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022551 0 14 24 62 51 33 12 32 18 44 181 80
2022/2023669 79 105 27 94 35 68 16 26 114 14 46 45
2023/2024194 24 25 12 20 15 47 11 4 13 13 6 4
2024/2025629 23 70 73 61 97 32 41 27 10 64 20 111
2025/20262.465 164 133 137 135 244 143 323 144 561 179 133 169
2026/2027114 64 50 0 0 0 0 0 0 0 0 0 0
Totale 6.148